Sanofi-a Ventis Deutschland Gmbh

Basf Aktiengesellschaft

Abbott Laboratories Corporation

Aventis Pharma S.a.

Abbott Gmbh & Co Kg

Volker Laux

Marc Nazare

Volkmar Wehner

Armin Bauer

Dieter Herr

Wilfried Hornberger

Andreas Kling

Hans Matter

Udo Lange

Kurt Ritter

Helmut Mack

Michael Wagner

Hervé Geneste

Matthias Urmann

Thomas Subkowski

Jörg Breitenbach

Christian Viskov

Pierre Mourier

Jörg Rosenberg

Arnulf Lauterbach

Robert Heger

Uta Holzenkamp

Claudia Isabella Graef

Jens Sadowski

F J Van Der Woude

Benito Yard

Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one &#x394;IIa-II-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described.

Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them

The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one heparin, glycosaminoglycan or heparinoid, and also a process for producing the formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as drug form, advantageously using melt extrusion, are described. The lipid component advantageously has active ingredient-promoting properties, while the polymer component is soluble or swellable. At least parts of the lipid component are embedded in a polymer matrix, preferably in the form of a molecular dispersion. The formulations can form emulsions in water or aqueous liquids.

Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base

The present invention relates to a compound of the formula I wherein J, J, R, R, R, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Indazole-derivatives as factor Xa inhibitors

The present invention is directed to the compound of formula I which is useful for inhibiting the activity of blood clotting enzyme Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically treating a patient suffering from, or subject to, a disease state associated with a cardiovascular disorder.

Triazole-derivatives as blood clotting enzyme factor Xa inhibitors

The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.

Indole derivatives as factor Xa inhibitors

The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.

Integrin receptors antagonists

The invention relates to the use of polysulfated glycosaminoglycans having a sulfur content of at least 12.5% for producing pharmaceutical preparations for inhibiting the &ggr;-interferon-induced upregulation of the MHC Class I and MHC Class II proteins and ICAM-1. The invention furthermore relates to organoprotective solutions comprising polysulfated glycosaminoglycans and to a process for the ex-vivo protection of transplant organs.

Organoprotective solutions

Growing community of inventors

Mainz, Germany

Volker Laux